Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS
Executive Summary
Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year.
You may also be interested in...
Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
10 Clinical Trials To Watch Out For In 2023
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.
Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod
Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.